DVAX - Dynavax Technologies Corporation
Pre-Market:
| Previous Close | 11.20 |
| Open | 11.19 |
| Bid | 10.97 x 1400 |
| Ask | 0.00 x 900 |
| Day's Range | 11.01 - 11.31 |
| 52 Week Range | 9.42 - 17.48 |
| Volume | |
| Avg. Volume | 1,284,257 |
| Market Cap | 1.443B |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | 7.20 |
| EPS (TTM) | 1.56 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.80 |
- Thomson Reuters StreetEvents
Q1 2023 Dynavax Technologies Corp Earnings Call
Q1 2023 Dynavax Technologies Corp Earnings Call
Motley FoolDynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including but not limited to, potential market sizes, market segmentation, future expected market share and related growth rates, and related ACIP recommendation impacts on each financial guidance and trends including revenue, profitability, insufficiency of current capitalization, and may results of clinical trial starts and data readouts and for potential future uses of or demand for our CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer; Donn Casale, chief commercial officer; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.
ZacksDynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -58.33% and 21.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.Dynavax Technologies (NASDAQ:DVAX) delivers shareholders solid 53% CAGR over 3 years, surging 6.4% in the last week alone
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- Simply Wall St.
Dynavax Technologies Corporation (NASDAQ:DVAX) Could Be Riskier Than It Looks
With a price-to-earnings (or "P/E") ratio of 4.1x Dynavax Technologies Corporation ( NASDAQ:DVAX ) may be sending very...
- Simply Wall St.
Need To Know: Analysts Just Made A Substantial Cut To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates
One thing we could say about the analysts on Dynavax Technologies Corporation ( NASDAQ:DVAX ) - they aren't optimistic...
- Thomson Reuters StreetEvents
Q4 2022 Dynavax Technologies Corp Earnings Call
Q4 2022 Dynavax Technologies Corp Earnings Call
- Motley Fool
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to, potential market sizes and market share, ACIP recommendation impact market trends, growth perspective, and rates, manufacturing plans, seasonality, financial guidance, and trends, including revenue, profitability and efficiency of current capitalization timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant. Joining me on the call today are: Ryan Spencer, chief executive officer; Donn Casale, senior vice president of commercial; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.
- Simply Wall St.
Dynavax Technologies Corporation's (NASDAQ:DVAX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dynavax Technologies (NASDAQ:DVAX) has had a rough three months with its share price down 14%. But if you pay close...
ZacksWall Street Analysts See a 109.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
The consensus price target hints at a 109.6% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksBlueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
ZacksDo Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
ZacksDynavax Technologies (DVAX) Upgraded to Strong Buy: Here's What You Should Know
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ZacksWall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 103.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireClover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements e
ZacksImplied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
- GlobeNewswire
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo -- -- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against
- Simply Wall St.
Dynavax Technologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Dynavax Technologies ( NASDAQ:DVAX ) Third Quarter 2022 Results Key Financial Results Revenue: US$167.7m (up 55% from...
- Zacks
Surging Earnings Estimates Signal Upside for Dynavax Technologies (DVAX) Stock
Dynavax Technologies (DVAX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ZacksAre Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZacksWall Street Analysts See a 154% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
The consensus price target hints at a 154.4% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksDynavax Technologies (DVAX) Recently Broke Out Above the 200-Day Moving Average
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
ZacksBest Value Stocks to Buy for November 7th
HDSN, CWBC and DVAX made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2022.
- Simply Wall St.
Downgrade: Here's How Analysts See Dynavax Technologies Corporation (NASDAQ:DVAX) Performing In The Near Term
Today is shaping up negative for Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders, with the analysts...
Motley FoolDynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share, ACIP impact, market trends, growth perspective, seasonality, financial guidance and trends, including revenue, profitability and sufficiency of current capitalization, timing of results of clinical trial starts and data readout, and potential future uses of CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer, Donn Casale, senior vice president of commercial, Rob Janssen, senior medical officer, and Kelly MacDonald, chief financial officer.
